samedan logo
 
 
 
spacer
home > ebr > summer 2003 > the biotech juggling act
PUBLICATIONS
European Biopharmaceutical Review

The Biotech Juggling Act

The completed sequencing of the human genome was a tremendous achievement but only 30 months later, the long-term knock on to the drug discovery industry is becoming apparent. The prediction is that by 2005 about half of all new products will come out of biotech; presumably this is why there are over 4,000 biotech-focused companies (approximately 10 per cent of which are public) out there.

Throughout these organisations computer-based research studies are increasing, and notably they are developing independently of the laboratory. Well-integrated information systems (IS) may one day develop into the primary R&D environment, with analytical laboratories reduced to a secondary role of investigative analysis and manufacturing. Consequently, I find myself wondering: how long before computer-based research overhauls traditional biological research and development?

Before I cause too much anxiety in the wet laboratory-based scientific community, let me elucidate what I mean by computer-based research. My view is that it includes, but is not restricted to, what many of you may already be thinking, namely the growing field of bioinformatics.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Geoff Parker, Commercial Director at Scimcon

Geoff Parker is Commercial Director at scientific information management consultancy Scimcon, where he is responsible for global sales and customer support. Geoff has a particular focus on data management strategy consultancy and enjoys a hands-on role advising clients on their information system requirements and system selection.

Before joining Scimcon in June 2000, Geoff spent two years with laboratory information system provider Thermo LabSystems. Prior to working in the lab information systems field, Geoff had a background in chemistry, working as a Technical Chemist, after which he spent five years working for a major technology supplier.

spacer
Geoff Parker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Syntegon and Vetter win PDA Drug Delivery Innovation Award for Versynta microBatch

Waiblingen/Germany, October 6, 2021. Together with Vetter, an international pharmaceutical service provider for injectables, Syntegon (formerly Bosch Packaging Technology) has won the PDA Drug Delivery Innovation Award. In the "Partnership Innovation" category, the Parental Drug Association (PDA) honors development projects by pharmaceutical and machine manufacturers that advance the production of (bio)pharmaceuticals. The collaboration between Vetter and Syntegon resulted in Versynta microBatch, a highly flexible and fully automated production cell with a gloveless isolator, the smallest possible dimensions and a complete batch-to-batch changeover of less than two hours.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement